截至7月11日，港股通创新药指数近一年累计上涨108.21%；港股创新药ETF（159567）连续5周实现份 额增长，累计增加8.89亿份。强劲涨幅叠加资金流入，反映出市场对创新药板块的高度关注与信心修 复。（数据来源：Wind，近一年统计区间2024.7.12至2025.7.11；连续5周时间区间2025.6.9至 2025.7.11，指数历史业绩不预示未来表现） 首先，创新药BD浪潮及港股二级市场回暖，有助于国内创新药融资环境改善。 2025年1-5月中国创新药 BD交易金额达5.98亿美金，合计已超2024年BD交易总额。另一方面，2025年上半年港股融资达884亿 港元，共有6家生物医药企业港股IPO，超过2024年全年总量。 （资料参考：21世纪经济报道《资本周 期中的突围：创新药企如何探寻破局之道？》，2025.7.13；每日经济新闻《今年以来新股募资额超884 亿港元跃居全球首位 港交所创立25年推动"东方之珠"成为国际金融中心》，2025.6.21；健康时报《半 年6家IPO超去年全年，政策红利掀起上市潮》，2025.7.2） 如何看待我国创新药市场持续升温？其背后，或是政策支持、资本加码与产 ...

证券代码：002038 证券简称：双鹭药业 双鹭药业上市公司投资者关系活动记录表 目前公司生产的硝酸甘油喷雾剂作为国内独家剂型具有良好的市 场前景，该产品在心绞痛、心梗时作为急救产品迅速起效十分重要，与 含片和气雾剂相比，硝酸甘油喷雾剂具有使用便捷、起效更快、安全性 更高的特点。近年来，心梗猝死的发病率逐年增高，且低龄化的趋势较 明显，主要与压力大、饮食和起居不规律有较大关系。目前，国内心血 管病患者约 3.3 亿，其中冠心病患者约 1100 万，心绞痛患者需常备急救 药物。我们认为该产品具有良好的市场潜力，公司会根据不同终端、不 同人群制定不同的推广策略，加大推广力度，通过学术会议、临床试验 数据分享、专家共识等方式传递产品价值。同时，公司也将加强与医药 销售不同渠道的合作，提高产品的市场覆盖率。努力使该产品成为公司 品牌产品。 4、介绍一下公司上市多年现金分红的情况。 公司 2024 年上市，首次募集资金 2.12 亿，此后再未进行过任何形 式的融资，公司重视股东回报，公司自 2004 年上市后每年都进行现金分 红，累计分红金额已超过 21 亿元，已超过募集资金十倍。 5、请介绍一下公司目前线上销售渠道。 ...

随着2024年底以来创新药板块逐步回暖，A股和港股市场均出现估值修复迹象。受益于监管优化、医保 支付政策稳定以及国际临床试验成果利好频出，细胞治疗、高端医疗器械等细分领域重新获得市场关 注。 三、高端医疗器械崛起，国产替代加速释放机会 在高端医疗器械方面，图湃医疗作为国产眼科设备平台型企业，依托清华工研院技术孵化，已实现眼科 OCT产品国内市占率第一，并在2024年8月完成眼科手术显微镜产品注册，步入销售加速期。图湃以 OCT为核心技术路径，正从眼科诊断设备向治疗设备拓展，并延伸至神经外科、五官科等临床场景，在 国产高端医疗器械进口替代趋势中占据稀缺优势。其在研产品如飞秒激光机器人、超乳玻切设备，以及 孵化的眼底注射机器人企业"瞳沐"，共同构成了眼科智能化手术平台的雏形。 此外，首程亦与药明康德等具备全球服务能力的CRO/CDMO平台保持合作。药明康德作为全球领先的 制药及医疗器械研发服务企业，其覆盖小分子药物发现至商业化、细胞与基因治疗全流程开发、医疗器 械测试等板块，为上游创新型药械企业提供关键研发基础设施支撑，进一步完善了首程产业投资逻辑中 的"技术—制造—应用"闭环。 四、政策与周期共振，产业型资本正 ...

证券代码：600420 证券简称：国药现代 公告编号：2025-057 上海现代制药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本公告所载上海现代制药股份有限公司（以下简称公司）2025 年半年度主 要财务数据为初步核算数据，未经会计师事务所审计，具体数据以公司 2025 年 半年度报告中披露的数据为准，提请投资者注意投资风险。 一、2025年半年度主要财务数据和指标 | | | | | | | 单位：人民币元 | | | | --- | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期 | | 增减变动幅度（%） | | | 营业总收入 | 4,877,673,521.93 | 5,960,093,922.86 | | -18.16 | | | 营业利润 | 920,163,725.85 | 1,096,704,023.68 | | -16.10 | | | 利润总额 | 924,926,954.05 | 1,086,401,902.24 | | -14.86 ...

麦济生物相关负责人介绍，在国内，MG-K10已经取得了显著的研究进展。在特应性皮炎适应症方面，MG-K10已成功完成临床Ⅱ期研究，为该药物的进 一步发展提供了有力的支持。目前，该产品正在中国进行特应性皮炎的注册Ⅲ期临床试验、哮喘的注册Ⅲ期临床试验、结节性痒疹的注册Ⅲ期临床试验及 季节性过敏性鼻炎的Ⅱ/Ⅲ期临床试验。 近日，湘江国投投资项目湖南麦济生物技术股份有限公司（以下简称"麦济生物"）正式向香港联合交易所递交上市申请书。 麦济生物是一家处于注册临床阶段的生物制药公司，致力于发现、开发及商业化创新生物制剂，以满足过敏性及自身免疫疾病等炎症性及免疫性疾病领域 未满足的医疗需求。 自2016年成立以来，麦济生物已自主研发并建立了由八款创新候选产品组成的管线，其中包括核心产品MG-K10、关键产品MG-014及MG-013，以及五款 其他候选产品。其中，三款候选产品已进入临床阶段。 通过结构改造，核心产品MG-K10以及关键产品MG-014和MG-013的半衰期延长，为市场上具有相同靶点的同类抗体的半衰期的2至3.5倍。麦济生物核心 产品MG-K10是一种潜在同类最佳、自主研发、处于注册临床阶段的长效抗IL-4R ...

Market Overview - The A-share market showed a positive trend today, with major indices mostly rising. The Shanghai Composite Index increased by 0.37% to close at 3516.83 points, while the Shenzhen Component rose by 1.43% to 10873.62 points. The ChiNext Index saw a gain of 1.75%, closing at 2269.33 points, and the Sci-Tech 50 Index increased by 0.80% to 1005.65 points. Overall, 3535 stocks rose, 1609 fell, and 271 remained unchanged, with a total trading volume of 15,394 billion yuan, an increase of 973 billion yuan from the previous trading day [1][2]. Industry Performance - Among the Shenwan first-level industries, the leading sectors included defense and military, communication, electronics, pharmaceutical and biological, and comprehensive industries, with respective gains of 2.74%, 2.41%, 2.18%, 1.77%, and 1.42%. Conversely, the banking, transportation, environmental protection, public utilities, and construction decoration sectors experienced declines, with losses of 0.42%, 0.39%, 0.26%, 0.24%, and 0.19% respectively [1][2]. Concept Sector Performance - The top-performing concept sectors today included circuit boards, CRO (Contract Research Organization), innovative drugs, aircraft carriers, first boards, medical services, board trading, large aircraft, continuous boards, wireless charging, the top ten military industrial groups, biological vaccines, photoresist, consumer electronics OEM, and 5G [2].

智通财经APP获悉，港股三大指数走势不一，恒指及国指早盘冲高回落并转跌，恒科指午后则一度涨近 1%。截止收盘，恒生指数跌0.08%或18.81点，报24498.95点，全日成交额为2364.12亿港元；恒生国企 指数跌0.09%，报8853.1点；恒生科技指数涨0.56%，报5448.85点。 东吴海外策略团队指出，对港股持谨慎乐观态度。港股下行相对有底，还在震荡向上趋势中，关注或有 增量资金入场。增配红利和寻找低估股票成为市场共识。中国银河证券认为，在全球权益市场中，港股 绝对估值处于相对低位水平、估值分位数处于历史中上水平，中长期配置价值仍然较高。 理想汽车-W(02015)领跑蓝筹。截至收盘，涨9.73%，报124.1港元，成交额49.36亿港元，贡献恒指24.08 点。理想汽车宣布理想i8开启预订，预计售价35万元人民币至40万元人民币，将于7月29日公布正式售 价，8月下旬开始交付。新车作为理想首款纯电SUV，市场关注度较高。 其他蓝筹股方面，中国生物制药(01177)涨5.9%，报6.82港元，贡献恒指6.22点；翰森制药(03692 )涨 4.39%，报34.5港元，贡献恒指2.69点；周大福( ...

Core Points - The National Medical Insurance Administration has officially launched the 11th batch of centralized procurement, including 55 drug varieties after a rigorous three-stage selection process [1][2] - This batch introduces a new sales threshold of 100 million yuan, excluding 24 varieties with sales below this threshold, reflecting a focus on drug quality and innovation [1][2] - The selection process emphasizes intellectual property protection, excluding drugs with unexpired patents and those with high clinical risks [2][3] Selection Criteria - A total of 122 candidate varieties were initially screened, with 55 ultimately selected based on criteria such as market scale, clinical expert opinions, and risk assessments [2][3] - Selected drugs cover various therapeutic areas, including anti-infectives, anti-tumor, diabetes, and cardiovascular medications [2] - Specific selection criteria include having at least seven companies for reference formulations and a procurement amount exceeding 100 million yuan in 2024 [2][3] Quality Control Measures - The new procurement rules raise the qualification requirements for bidders, mandating at least two years of production experience for the drug's manufacturing entity [3] - The National Medical Products Administration will implement comprehensive inspections and product sampling to ensure the quality of selected drugs [3][4] - In 2024, the administration aims for 100% coverage of selected varieties and enterprises through a combination of national and local sampling [3][4] Reporting and Quoting Adjustments - The new rules allow medical institutions to report quantities based on specific brands rather than generic names, aligning supply with clinical needs [4][5] - Institutions are required to report quantities that are at least 80% of actual usage, with flexibility for adjustments based on clinical demand [4][5] - The procurement process will also address irrational low-price competition and supply risks through updated bidding rules and penalties [5][6] Policy Evolution - The 11th batch of procurement marks a shift from a focus solely on low prices to a dual emphasis on quality and price [7] - The centralized procurement initiative has been ongoing for seven years, covering 435 drug varieties and significantly reducing drug prices for the public [7]

恒瑞医药(600276.SH)公告称，公司及子公司收到国家药监局核准签发关于SHR-8068注射液、阿得贝利 单抗注射液、贝伐珠单抗注射液、甲磺酸阿帕替尼片的《药物临床试验批准通知书》，将于近期开展临 床试验。SHR-8068注射液是全人源抗CTLA-4单克隆抗体，阿得贝利单抗注射液是自主研发的人源化抗 PD-L1单克隆抗体，贝伐珠单抗注射液是一种人源化抗VEGF单克隆抗体，甲磺酸阿帕替尼片是创新研 发的小分子靶向药物。这些药物的研发投入分别为SHR-8068注射液约2.14亿元，阿得贝利单抗注射液 约8.87亿元，贝伐珠单抗注射液约3.45亿元，甲磺酸阿帕替尼片约5.87亿元。根据相关法律法规要求， 药物在获得药物临床试验批准通知书后，尚需开展临床试验并经国家药监局审评、审批通过后方可生产 上市。 ...

Group 1 - The core viewpoint of the articles highlights Yiling Pharmaceutical's significant achievements in the field of innovative traditional Chinese medicine, showcasing its strong R&D capabilities and successful product registrations [1][2][3] - Yiling Pharmaceutical's R&D investment reached 908 million yuan in 2024, accounting for 13.94% of its revenue, indicating a leading position in the industry regarding R&D intensity [1] - The company has multiple products in various stages of clinical trials, including six new traditional Chinese medicine varieties, and has successfully registered the classic formula Banxia Baizhu Tianma Decoction [1][2] Group 2 - Yiling Pharmaceutical's chemical drug segment is also accelerating, with its subsidiary Yiling Wanzhou focusing on the development of innovative drugs, including the NDA application for Anilofin Injection [2] - The company reported a revenue of 2.358 billion yuan and a net profit of 326 million yuan for the first quarter of 2025, reflecting a year-on-year growth of 7.25% and 11.23% respectively [2] - The company has established a competitive R&D system and product reserve in the respiratory and cardiovascular fields, supported by the theory of collateral diseases [2]